ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Terumo Corp.

  • 3,194.00 JPY
  • -75.00
  • -2.29%
  • Japan
    Aug 23, 2019
  • Ticker
    TKS(4543)
  • Prev. close
    3,269
  • Market cap (JPY)
    2,482.87B
  • Market cap (USD)
    23,281.70M
  • Shares
    759.52M

Business Summary

Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan

Financial Highlights

Mar 2019 JPYUSD
Revenue599,481M5,405.85M
Gross Profit312,203M2,815.31M
Operating income100,621M907.35M
Income before tax102,709M926.18M
Net income79,470M716.62M
EBITDA144,656M1,304.44M
Diluted EPS104.960.94
Dividends Per Share270.24
Total Assets1,120.79B10,125.94M
Total liabilities422,674M3,818.71M
Total equity698,034M6,306.49M
Operating cash flow93,571M843.78M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 489,506M 525,026M 514,164M 587,775M 599,481M
Gross Profit 256,026M 284,901M 261,259M 305,629M 312,203M
Operating income 67,456M 81,703M 90,547M 106,970M 100,621M
Income before tax 64,046M 76,920M 74,881M 106,630M 102,709M
Net income 38,470M 50,676M 55,002M 91,295M 79,470M
EBITDA 108,148M 126,377M 125,018M 149,005M 144,656M
Diluted EPS 49.56 63.18 71.37 121.03 104.96
Dividends Per Share 15.25 19.50 21 25 27
Total Assets 992,073M 901,685M 1,022.26B 1,081.04B 1,120.79B
Total liabilities 418,550M 390,141M 530,735M 530,606M 422,674M
Total equity 573,523M 511,435M 491,421M 550,307M 698,034M
Operating cash flow 73,110M 80,303M 82,888M 114,562M 93,571M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 4,455.86M 4,372.14M 4,748.13M 5,303.27M 5,405.85M
Gross Profit 2,330.54M 2,372.50M 2,412.64M 2,757.57M 2,815.31M
Operating income 614.03M 680.38M 836.17M 965.15M 907.35M
Income before tax 582.99M 640.55M 691.50M 962.08M 926.18M
Net income 350.18M 422.00M 507.92M 823.72M 716.62M
EBITDA 984.44M 1,052.40M 1,154.50M 1,344.41M 1,304.44M
Diluted EPS 0.45 0.52 0.65 1.09 0.94
Dividends Per Share 0.13 0.16 0.19 0.22 0.24
Total Assets 8,272.44M 8,022.46M 9,174.02M 10,164.97M 10,125.94M
Total liabilities 3,490.09M 3,471.15M 4,762.94M 4,989.24M 3,818.71M
Total equity 4,782.34M 4,550.33M 4,410.13M 5,174.48M 6,306.49M
Operating cash flow 665.50M 668.72M 765.44M 1,033.65M 843.78M

Valuation Measures

Mar 2019
PER31.09
ROA7.21%
ROE12.73%
Operating margin16.78%
Profit margin13.25%

Key executives

  • President, CEO & Representative Director: Shinjiro Sato
  • Chief Accounting & Financial Officer: Ryo Nishihata
  • Chief Clinical & Regulatory Affairs Officer: Kazuhisa Senshu
  • Chief Information Officer & Executive Officer: Katsuya Takeuchi
  • CTO, Executive Officer, Head-R&D Promotions: Hiroaki Kasukawa

Shareholders

  • Nomura Asset Management Co., Ltd. (7.3%)
  • Massachusetts Financial Services Co. (6.0%)
  • Dai-ichi Life Holdings, Inc. (4.5%)
  • Nikko Asset Management Co., Ltd. (4.0%)
  • Meiji Yasuda Life Insurance Co. (3.5%)
  • Daiwa Asset Management Co. Ltd. (3.4%)
  • Mitsubishi UFJ Financial Group, Inc. (2.8%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.5%)
  • The Vanguard Group, Inc. (2.2%)
  • Terumo Corp. (2.1%)

Contact Details

  • Website:http://www.terumo.co.jp
  • Address: 2-44-1 Hatagaya, Shibuya-Ku, Tokyo, 151-0072, Japan
  • Phone: +81.3.3374.8111

Related Companies

  • Terumo Restricted Stock Compensation Plan
  • Essen Technology Pte Ltd.
  • TP Estate, Inc.
  • Terumo BCT Caribe CA
  • Terumo BCT Portugal Unipessoal Lda.
  • Terumo Russia LLC
  • Terumo BCT Biotechnologies LLC
  • Terumo Colombia Andina SAS
  • Terumo BCT Colombia SA
  • Terumo BCT Uruguay SA
  • Terumo BCT Peru SAC
  • Terumo Panama International, Inc.
  • Terumo Mauritius Holding Ltd.
  • Terumo India Pvt Ltd.
  • Terumo BCT (Hong Kong) Ltd.
  • Terumo Medical (Shanghai) Co. Ltd.
  • Terumo Vietnam Medical Equipment Co. Ltd.
  • MicroVention Europe SARL
  • PT Terumo Indonesia
  • Terumo Singapore Pte Ltd.
  • Terumo Marketing Philippines, Inc.
  • Terumo BCT Vietnam Co. Ltd.
  • Terumo BCT Latin America SA
  • Terumo Medical de Mexico SA de CV
  • Terumo BCT Mexico SA de CV
  • Terumo Malaysia Sdn. Bhd.
  • Terumo BCT Medical Product Trading (Shanghai) Ltd.
  • Terumo BCT Tecnologia Medica Ltda.
  • Terumo Vietnam Co. Ltd.
  • Terumo China (Hong Kong) Ltd.

Competitors

  • Getinge AB Class B
  • Merit Medical Systems, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Fresenius SE & Co. KGaA
  • Silk Road Medical, Inc.
  • Stryker Corporation
  • InspireMD, Inc.
  • LeMaitre Vascular, Inc.
  • LivaNova Plc
  • CryoLife, Inc.
  • Haemonetics Corporation
  • AngioDynamics, Inc.
  • Lombard Medical Inc
  • CollPlant Biotechnologies Ltd Sponsored ADR
  • Hancock Jaffe Laboratories, Inc.
  • Penumbra, Inc.
  • Guerbet SA
  • BTG plc
  • ABIOMED, Inc.
  • Cellect Biotechnology Ltd Sponsored ADR
  • Cellular Biomedicine Group, Inc.
  • Cerus Corporation
  • Nephros, Inc.
  • PSB Industries SA
  • Retractable Technologies, Inc.
Last Updated on 23 Aug, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media